Briumvi 150 mg Infusion Overview: Uses, Warnings & FAQs
Quick summary Briumvi 150 mg concentrate for solution for infusion contains ublituximab and is used for adult patients with relapsing forms of multiple sclerosis (RMS) with active disease. It is given by intravenous infusion...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Briumvi 150 mg concentrate for solution for infusion contains ublituximab and is used for adult patients with relapsing forms of multiple sclerosis (RMS) with active disease. It is given by intravenous infusion in a clinical setting, with monitoring for infusion-related reactions and other safety concerns.
Medical disclaimer
This article is for general information only and does not replace the official patient leaflet, product information, or advice from a qualified healthcare professional. Treatment decisions, infusion schedules, and safety checks should always be confirmed by the prescribing team.
What is Briumvi 150 mg concentrate for solution for infusion?
Briumvi is an intravenous medicine used in adults with relapsing forms of multiple sclerosis (RMS). Its active substance is ublituximab, a chimeric monoclonal antibody that targets CD20 on B cells.
By reducing CD20-positive B cells, Briumvi is used to help manage active disease. It is administered as an infusion in a healthcare setting rather than taken at home.
What is it used for?
The content provided describes Briumvi as being indicated for adult patients with active relapsing multiple sclerosis. The aim of treatment is to help manage disease activity and reduce relapses.
- Used in adults with relapsing forms of multiple sclerosis
- Targets CD20-positive B cells
- Given as a monitored infusion
How is Briumvi administered?
Briumvi is given by intravenous infusion by a qualified healthcare professional. The article notes that premedication with steroids and antihistamines is used to help reduce the risk of infusion-related reactions.
The treatment schedule described in the source content is:
- An initial infusion of 150 mg
- A second infusion of 450 mg two weeks later
- Further infusions every 24 weeks
Because infusion medicines can cause reactions during administration, patients are typically monitored closely during and after the infusion.
Warnings and precautions
The source content highlights several important precautions. These should be reviewed with the prescribing clinician and checked against the official leaflet.
- Infusion-related reactions: monitoring is important during treatment.
- Serious infections: the risk of infection should be considered.
- Hepatitis B screening: screening is required before the first dose.
- Allergy history: a history of severe allergy to ublituximab is relevant.
- Immune system status: patients with a compromised immune system need careful assessment.
If a patient has an active infection or a history of severe infusion reactions, these factors should be discussed with the healthcare team before treatment is given.
Possible adverse reactions
The content identifies both common and serious adverse reactions. Reported common reactions include headache, nausea, and infusion-related symptoms such as fever or chills.
More serious reactions can include infections. Because of this, ongoing monitoring is important during treatment and afterwards if symptoms develop.
What should patients know during treatment?
Patients receiving Briumvi should understand the importance of attending scheduled infusions and following the monitoring plan set by their healthcare team.
- Keep infusion appointments as planned
- Report new or worsening symptoms promptly
- Read the Patient Information Leaflet (PIL) carefully
- Ask the healthcare team about any concerns before treatment
The PIL is especially useful for recognising symptoms that may need urgent medical attention.
Dosage form and strength
Briumvi is supplied as a concentrate for solution for infusion. The content provided states that each vial contains 150 mg of ublituximab.
This formulation is intended for dilution and intravenous administration by healthcare professionals.
At a glance
| Topic | Summary |
|---|---|
| Active ingredient | Ublituximab |
| Use | Adult patients with active relapsing forms of multiple sclerosis |
| Route | Intravenous infusion |
| Key precautions | Infusion reactions, infections, hepatitis B screening |
Frequently asked questions
▸ What is a concentrate for solution for infusion?
It is a medicine that must be diluted before being given as an infusion. It is prepared and administered by healthcare professionals.
▸ Why is Briumvi given in a clinic or hospital?
It is an intravenous infusion and the source content notes the need for monitoring and premedication to help reduce infusion-related reactions.
▸ What side effects are mentioned in the source content?
Headache, nausea, fever, chills, and infections are mentioned. The official leaflet should be checked for the full list.
▸ Is hepatitis B screening important before treatment?
Yes. The source content states that hepatitis B screening is required before the first dose.
▸ What should a patient do if they feel unwell after an infusion?
They should contact their healthcare team promptly, especially if symptoms suggest an infusion reaction or infection.
Safety reminder
Do not rely on this overview alone for treatment decisions. Infusion medicines require professional supervision, and safety checks such as infection screening and reaction monitoring should be confirmed with the prescribing team or official product information.
Related questions about infusion medicines
▸ What is Brevibloc premixed 10 mg/mL solution for infusion?
Brevibloc is another infusion medicine used for certain heart conditions. Its use and monitoring requirements are different from Briumvi.
▸ What is concentrate for solution for infusion levetiracetam?
Levetiracetam can also be supplied as an infusion concentrate, usually when oral treatment is not suitable.
▸ What is Thymoglobuline powder for solution for infusion?
Thymoglobuline is an immunosuppressive infusion medicine used in transplant-related care and requires reconstitution before administration.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.